ImmuronASX:IMC +8.33% Receivables Turnover is 4.71 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 839 Biotechnology companies, Immuron ranks better than 68.06% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Immuron's Revenue for the
six
months ended in Dec. 2025 was A$4.18 Mil. Immuron's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.89 Mil.
Hence, Immuron's Receivables Turnover for the
six
months ended in Dec. 2025 was 4.71.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Immuron Receivables Turnover Related Terms
Immuron Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Immuron's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMC vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Immuron's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Immuron's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (ASX:IMC) has a Receivables Turnover of 4.71 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Immuron and its competitors. According to the industry distribution chart, Immuron ranks #268 out of 839 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Immuron's Receivables Turnover too high?
Immuron's current Receivables Turnover is 4.71. The Biotechnology industry median Receivables Turnover is 5.27. Immuron's value of 4.71 is 10.6% below this industry median. Based on the distribution chart, Immuron ranks #268 out of 839 companies in the Biotechnology industry, which is above the industry midpoint.
How does Immuron's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #268 out of 839 companies for Receivables Turnover. This puts Immuron in the upper half of its industry. The industry median Receivables Turnover is 5.27. Immuron's value of 4.71 is 10.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuron's current Receivables Turnover of 4.71 is 10.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Immuron and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current Receivables Turnover is 4.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (ASX:IMC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.04 — trading 83% below its estimated fair value. The current Receivables Turnover is 4.71 and 10.6% below the Biotechnology industry median of 5.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Immuron (ASX:IMC), the current Receivables Turnover is 4.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMC has been successfully added to your 